​Join Galderma for an exclusive webinar on Relfydess™ (RelabotulinumtoxinA), the first and only ready-to-use liquid neuromodulator developed using PEARL™ Technology.

​This session is designed to provide healthcare practitioners with in-depth knowledge of the science and clinical applications of Relfydess™.

In this webinar, you will:

​1. Discover the science and clinical use of Relfydess to treat glabellar and lateral canthal lines

​2. Discuss the key clinical benefits with Relfydess for you, your patient and your clinic

​3. Outline approved indications and recommended dosing

​Key Take Aways:

​Designed for Aesthetic use and with 2 indications approved at launch, Relfydess is the first neuromodulator in a ready-to-use liquid formulation manufactured with PEARL technology.

​Optimised liquid formulation, for simple volumetric dosing, which is convenient and time-saving ensuring you spend more time with your patients and provides consistency with every vial every treatment.

​Developed by Galderma with your patients in mind, Relfydess demonstrates:

• ​Fast onset within 24 hours in 39% of patients

• ​High patient satisfaction (97% highly satisfied after 1 month with up to 86% agreeing through 6 months)

• ​Long-lasting results through 6 months in 75% of patients

​Relfydess recommended dosing: (AUS PI) – 0.1mL (10 units)

• ​Glabellar lines: 0.5mL (50 units)

• ​Lateral canthal lines: 0.6mL (60 units) which means 0.3mL (30 units)
  
  Consultation that includes Facial assessment is paramount. By uncovering the need for combination treatments results in higher client/patient satisfaction and better retention, more word of mouth referral and business growth. Antiwrinkle treatments may be the first foray into cosmetic or aesthetic journey so it is critical to satisfy at the first treatment, and keep this client/patient.

​

Speaker:

​Deborah Bottema

​Debi Bottema is a registered nurse with a background in Burns and Plastic Surgical nursing as well as education, management and people leadership. Debi was the clinical manager at Q-Med ANZ 1997 – 2012, before joining Galderma where she leads Aesthetic Healthcare Practitioner clinical training and education and developing the clinical nurse specialist team.

​Debi was instrumental in the successful launch of Restylane into Australia and New Zealand as well as Canada. She has educated many Healthcare practitioners locally and internationally including throughout Asia. She is passionate about best practice in aesthetics to ensure optimal treatment outcomes and high patient satisfaction.

​Debi is a proven leader and strong advocate within Aesthetic medicine who contributes with unbridled enthusiasm and passion to empower others to achieve their learning goals